| Authors: |
Landsburg DJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. daniel.landsburg@pennmedicine.upenn.edu., Musoke N; Lymphoid Malignancies Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Gentile C; Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Brooks TR; Lymphoid Malignancies Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Nasta SD; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Barta SK; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Carter JS; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Chong EA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Svoboda J; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Thomas CJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Tomasulo EB; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Cook MR; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Morrissette JJD; Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Caimi PF; Lymphoid Malignancies Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Hill BT; Lymphoid Malignancies Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. |
